Clinical Trials Logo

Clinical Trial Summary

The pathophysiological mechanisms that underlie primary headache disorders, such as migraine and cluster headache (CH), are complex and not yet fully clarified. While there is today little doubt that activation of the trigeminovascular system (TGVS) is responsible for the headache pain, the primary mechanisms, probably centrally mediated, leading to its activation and the generation of pain are still largely obscure. The trigeminal system is supposed to play a central role not only in migraine but also in cluster headache pathology. In vitro studies have demonstrated the expression of BDNF in trigeminal ganglion neurons. BDNF release is induced by trigeminal stimulation and nociceptive inputs. BDNF is a member of the neurotrophin family and has been recognized as an important modulator of nociceptive pathways. Interestingly, BDNF is co-expressed with CGRP in trigeminal ganglion neurons. CGRP is one of the key molecules in migraine and cluster headache pathogenesis. BDNF is an important marker of neuronal plasticity. It has also been associated with pain processing. Increased BDNF levels are observed in chronic pain syndromes. In order to understand the role of BDNF associated with other factors such as gender on headache attacks we aimed to determine whether migraine and cluster headache is correlated with brain derived neurotrophic factor (BDNF) level, gender and age.


Clinical Trial Description

Patients will recruite among those attending the Clinic of Tashkent Medical Academy, Uzbekistan. Three groups of headache patients will be enrolled in this prospective study: patients with episodic migraine with and without aura, episodic cluster headache, and frequent episodic tension-type headache according to the current criteria of the International Headache Society. In migraineurs, venous blood samples will be collected twice: outside and during migraine attacks prior to pain medication. In cluster headache patients serum samples will be collected in and outside cluster bout. Analysis of BDNF will performed using enzyme-linked immunosorbent assay technique. In patients with tension-type headache (outside attack) and healthy controls, one single blood sample will take.Patients with a history of cardiovascular disease, major depression, hypertension, drug or alcohol abuse, or other apparent diseases will be excluded from the study. The research will comprise 120 patients (males and females) suffering from primary headache. At the moment we started collecting patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05760625
Study type Observational [Patient Registry]
Source Tashkent Medical Academy
Contact
Status Enrolling by invitation
Phase
Start date December 10, 2020
Completion date March 21, 2023

See also
  Status Clinical Trial Phase
Completed NCT00449787 - Comparing Naproxen to Sumatriptan for Emergency Headache Patients Phase 4
Recruiting NCT04080258 - Effectiveness of Osteopathic Manipulative Therapy in Paediatric Patients, With High Frequency Headache. N/A
Completed NCT05511155 - Oxygen Therapy for Headache
Active, not recruiting NCT04178252 - Effectiveness of Eye Mask and Noise Reduction Headset in Primary Headache N/A
Not yet recruiting NCT05057533 - Primary Headaches and Irritable Bowel Syndrome.
Withdrawn NCT05337930 - Feasibility of a Developmentally-tailored Mobile App for Tracking Mood and Pain in Children With Migraine N/A
Active, not recruiting NCT05023460 - Treatment of Chronic Cluster Headache With TENS and ONS N/A
Recruiting NCT03499392 - Primary Headache and Psychological Factors, Mental Functioning and Attachment Modalities. N/A